CLN7 — Ceroid Lipofuscinosis, Neuronal 7 (MFSD8)

Migration, Crosslink

📖

CLN7 — Ceroid Lipofuscinosis, Neuronal 7 (MFSD8)

active

wiki page Created: 2026-04-02T07:19:25 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-cln7

📖 Wiki Page

gene2732 wordssynced 2026-04-02

CLN7 — Ceroid Lipofuscinosis, Neuronal 7

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CLN7 — Ceroid Lipofuscinosis, Neuronal 7 (MFSD8)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CLN7 / MFSD8</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Major Facilitator Superfamily Domain Containing 8</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>4q28.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>256281</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>614804</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000167695</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q8N5M4</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>MFS transporter, lysosomal membrane protein</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Brain, retina, liver, kidney, lung</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Onset Age</td>
</tr>
<tr>
<td class="label">Classic LINCL</td>
<td>2-7 years</td>
</tr>
<tr>
<td class="label">Early juvenile</td>
<td>4-5 years</td>
</tr>
<tr>
<td class="label">Slowly progressive</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Adult-onset</td>
<td>18+ years</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">c.881G>A (p.Arg294His)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">c.964C>T (p.Arg322X)</td>
<td>Non

...

CLN7 — Ceroid Lipofuscinosis, Neuronal 7

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CLN7 — Ceroid Lipofuscinosis, Neuronal 7 (MFSD8)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CLN7 / MFSD8</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Major Facilitator Superfamily Domain Containing 8</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>4q28.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>256281</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>614804</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000167695</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q8N5M4</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>MFS transporter, lysosomal membrane protein</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Brain, retina, liver, kidney, lung</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Onset Age</td>
</tr>
<tr>
<td class="label">Classic LINCL</td>
<td>2-7 years</td>
</tr>
<tr>
<td class="label">Early juvenile</td>
<td>4-5 years</td>
</tr>
<tr>
<td class="label">Slowly progressive</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Adult-onset</td>
<td>18+ years</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">c.881G>A (p.Arg294His)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">c.964C>T (p.Arg322X)</td>
<td>Nonsense</td>
</tr>
<tr>
<td class="label">c.1087C>T (p.Arg363X)</td>
<td>Nonsense</td>
</tr>
<tr>
<td class="label">c.1334G>A (p.Arg445His)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Specialist</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Pediatric Neurologist</td>
<td>Seizure management, overall care coordination</td>
</tr>
<tr>
<td class="label">Ophthalmologist</td>
<td>Visual impairment assessment and aids</td>
</tr>
<tr>
<td class="label">Physical Therapist</td>
<td>Motor function maintenance</td>
</tr>
<tr>
<td class="label">Occupational Therapist</td>
<td>Daily living skills</td>
</tr>
<tr>
<td class="label">Speech Therapist</td>
<td>Communication support</td>
</tr>
<tr>
<td class="label">Dietitian</td>
<td>Nutritional assessment</td>
</tr>
<tr>
<td class="label">Genetic Counselor</td>
<td>Family counseling</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">AAV-MFSD8</td>
<td>Direct gene replacement</td>
</tr>
<tr>
<td class="label">AAV-CNTF + AAV-MFSD8</td>
<td>Combined therapy</td>
</tr>
<tr>
<td class="label">CNS-targeted AAV</td>
<td>Enhanced brain delivery</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

CLN7 (Ceroid Lipofuscinosis, Neuronal 7), also known as MFSD8 (Major Facilitator Superfamily Domain Containing 8), is a human gene that encodes a lysosomal membrane protein functioning as a putative transporter. Biallelic mutations in CLN7 cause Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL), a fatal neurodegenerative storage disease characterized by progressive neurodegeneration, visual loss, seizures, and premature death[@siintola2007].

CLN7 is a member of the Major Facilitator Superfamily (MFS) of transporters, a large family of secondary active transporters that move small molecules across membranes in response to electrochemical gradients. This gene is crucial for lysosomal function and neuronal survival.

CLN7 disease is classified among the neuronal ceroid lipofuscinoses (NCLs), a group of inherited neurodegenerative disorders also known as Batten disease. The CLN7 phenotype typically presents as a variant late-infantile onset form, with disease onset between 2-7 years of age[@kousi2009].

Gene Information

Protein Structure and Function

MFSD8 Structure

MFSD8 is a 476-amino acid lysosomal membrane protein:

N-terminal signal peptide: Targets protein to lysosomal membrane
12 transmembrane domains: Characteristic of MFS transporters
Large extracellular loop: Between transmembrane domains 1 and 2
Conserved MFS motifs: Characteristic sequence features of the superfamily

Lysosomal Transporter Function

MFSD8 functions as a lysosomal membrane transporter:

Substrate specificity: Likely transports small molecules across lysosomal membrane (specific substrates not fully characterized)
Lysosomal homeostasis: Maintains lysosomal pH and ion balance
Autophagy support: Facilitates lysosomal function during [autophagy](/mechanisms/autophagy)
Lipid transport: May transport lipids or lipid-derived molecules

Expression Pattern

MFSD8 is expressed in multiple tissues:

Brain: High expression in [neurons](/entities/neurons), especially in cortex and cerebellum
Retina: Photoreceptor layer expression (explains visual loss in CLN7 disease)
Liver: Hepatocytes
Kidney: Renal tubular cells
Lung: Epithelial cells

Normal Biological Function

Lysosomal Transport

MFSD8 is predicted to function as a lysosomal transporter mediating the flux of small molecules across the lysosomal membrane. Based on homology to other MFS proteins, MFSD8 likely transports:

Amino acids and small peptides
Organic anions and cations
Sugar derivatives
Neurotransmitter metabolites

The exact substrate specificity of MFSD8 remains to be definitively characterized, though functional studies suggest it may transport carnitine derivatives or related metabolites important for neuronal homeostasis.

Autophagy and Lysosomal Function

MFSD8 plays an essential role in autophagic-lysosomal pathway function. Studies in Drosophila and mammalian models demonstrate that MFSD8 loss leads to:

Impaired autophagic flux
Accumulation of autophagic debris
Lysosomal storage material accumulation
Mitochondrial dysfunction

Loss of CLN7 function disrupts normal autophagic degradation, leading to accumulation of abnormal membranous material and lipofuscin-like deposits in neurons[@leonard2016].

Neuronal Homeostasis

In neurons, MFSD8 contributes to:

Synaptic vesicle maintenance - ensuring proper neurotransmitter release
Mitochondrial quality control - through mitophagy regulation
Calcium homeostasis - lysosomal calcium stores
Lipid trafficking - between cellular compartments

The protein is highly expressed in neurons of the cerebral cortex, hippocampus, and cerebellum, as well as in photoreceptor cells of the retina[@mohammed2017].

Disease Mechanism

Pathogenesis Overview

CLN7 disease pathogenesis involves accumulation of ceroid lipofuscin - autofluorescent lipopigments composed of lipid-rich membranous material - within lysosomes of neurons and other cell types. This accumulation results from impaired lysosomal function due to MFSD8 deficiency.

The fundamental defect involves:

Loss of MFSD8 transporter function

Impaired lysosomal degradation capacity

Accumulation of substrate material

Secondary cellular dysfunction

Progressive neuronal death

Molecular Pathogenesis

Studies in cellular and animal models have revealed several key pathogenic mechanisms:

Glycolytic Dysregulation: Recent research demonstrates aberrant upregulation of PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3) in CLN7 disease, leading to increased glycolytic flux and metabolic reprogramming in affected neurons. This glycolytic shift contributes to oxidative stress and neuronal dysfunction[@lopez2022].

Mitochondrial Dysfunction: MFSD8 deficiency leads to impaired mitochondrial quality control, characterized by:

Accumulation of damaged mitochondria
Reduced respiratory chain activity
Increased reactive oxygen species (ROS) production
Disrupted cellular bioenergetics

Autophagy Inhibition: The autophagic-lysosomal pathway is significantly impaired in CLN7 disease. LC3-positive autophagosomes accumulate, indicating blocked autophagic flux. This defect prevents clearance of damaged organelles and protein aggregates[@leonard2016].

Lysosomal Storage: The characteristic ceroid lipofuscin accumulation represents undigested lipid-rich membrane material. These deposits contain:

Mitochondrial debris
Membrane fragments
Oxidized proteins
Lipid aggregates

Neuroinflammation

CLN7 disease involves significant neuroinflammatory responses, including:

Activated microglia in affected brain regions
Elevated pro-inflammatory cytokines (IL-1β, TNF-α)
Reactive astrocytosis
Secondary excitotoxicity

Neuroinflammation contributes substantially to disease progression and represents a potential therapeutic target.

Clinical Presentation

Typical Disease Course

CLN7 disease follows a predictable but variable clinical course:

Pre-symptomatic phase: Normal development until disease onset Early stage (2-5 years):

Initial developmental plateau
Language regression
Motor skill deterioration

Middle stage (5-10 years):

Progressive visual loss
Intractable seizures
Severe intellectual disability
Ataxia and motor regression

Late stage (10+ years):

Total blindness
Progressive myoclonus
Loss of ambulation
Severe neurocognitive decline
Premature death (often in adolescence or early adulthood)

Core Clinical Features

Seizures: Typically the presenting symptom in many patients. Seizure types include:

Focal seizures
Myoclonic seizures
Generalized tonic-clonic seizures
Atypical absence seizures

Visual Loss: Progressive retinal degeneration leading to complete blindness. Fundoscopic examination reveals:

Optic nerve pallor
Retinal vessel attenuation
Macular degeneration

Motor Regression: Progressive loss of motor skills including:

Gait instability
Loss of fine motor control
Hypotonia progressing to spasticity

Cognitive Decline: Progressive intellectual disability:

Initial learning difficulties
Progressive language loss
Global neurocognitive regression

Speech and Language:

Early language delay
Progressive aphasia
Loss of verbal communication

Disease Subtypes

Diagnostic Findings

Neuroimaging:

Cerebral atrophy (progressive)
Cerebellar atrophy
White matter changes
Ventricular enlargement

EEG: Progressive slowing with epileptiform activity

Ophthalmologic: Retinitis pigmentosa-like changes

Enzyme/Metabolite:

Elevated lysosomal storage markers
Abnormal plasma biomarkers

Genetics

Inheritance Pattern

CLN7 disease follows autosomal recessive inheritance. Affected individuals have two pathogenic alleles:

Compound heterozygous (two different mutations) - most common
Homozygous (identical mutations) - less common

Parents are typically heterozygous carriers who are phenotypically normal.

Mutation Spectrum

Over 70 pathogenic variants have been identified in CLN7/MFSD8, including[@kousi2012]:

Missense variants (~60%):

Most common mutation type
Often result in partially functional protein
Variable residual activity correlates with phenotype

Nonsense variants (~20%):

Generate premature stop codons
Result in truncated, non-functional protein
Typically associated with severe phenotype

Splice site variants (~15%):

Disrupt normal RNA splicing
May produce in-frame deletions or exon skipping
Variable severity depending on affected exon

Small insertions/deletions (~5%):

Frameshift mutations
Usually severe functional impact

Common Variants

Genotype-Phenotype Correlations

Certain genotype combinations correlate with phenotype severity:

Two null alleles → severe, early onset
Missense + missense → variable, often later onset
Missense + null → intermediate severity

Expression Patterns

Tissue Distribution

MFSD8 is widely expressed with highest levels in:

Neural tissues:

Cerebral cortex (layer 5 neurons)
Hippocampus (CA1-CA3 pyramidal cells)
Cerebellum (Purkinje cells)
Retina (photoreceptor cells)
Spinal cord (motor neurons)

Peripheral tissues:

Liver (hepatocytes)
Kidney (tubular cells)
Lung (alveolar epithelium)
Skeletal muscle
Heart

Developmental Expression

MFSD8 expression is developmentally regulated:

Low expression in fetal brain
Increases significantly postnatally
Highest expression in adult brain
Declines with age

This pattern suggests MFSD8 is particularly important for maintenance of mature neurons rather than development.

Cell-Type Specificity

Within the brain, MFSD8 is enriched in:

Excitatory glutamatergic neurons
GABAergic interneurons
Certain glial cells (astrocytes, microglia)

Signaling and Pathway

Mermaid diagram (expand to render)

Animal Models

Canine Model

A naturally occurring CLN7 model exists in Chihuahuas and other dog breeds, caused by a MFSD8 mutation. This model recapitulates key features of human CLN7 disease[@ashwini2016]:

Progressive neurodegeneration
Visual loss
Seizures
Lysosomal storage accumulation

The canine model has been valuable for studying disease progression and therapeutic interventions.

Drosophila Model

Drosophila melanogaster models of CLN7 have been developed through:

RNAi-mediated knockdown
CRISPR-based knockouts

These models demonstrate:

Lifespan reduction
Locomotor defects
Accumulation of autofluorescent material
Impaired autophagy[@leonard2016]

Mouse Models

Several mouse models are under development:

Conditional knockout models
Humanized mouse models with patient mutations
Knock-in models with common pathogenic variants

Biomarkers and Diagnostic Markers

Fluid Biomarkers

Blood Biomarkers:

Elevated lysosomal enzyme activities
Increased inflammatory cytokines (IL-6, TNF-α)
Altered metabolite profiles

Cerebrospinal Fluid Biomarkers:

Elevated total protein
Increased tau and neurofilament light chain (NfL)
Decreased β-amyloid 1-42 in some cases

Imaging Biomarkers

Magnetic Resonance Imaging (MRI):

Progressive cerebral atrophy
Cerebellar atrophy
White matter hyperintensities
Ventricular enlargement

Positron Emission Tomography (PET):

TSPO binding showing microglial activation
Fluorodeoxyglucose (FDG) hypometabolism in specific brain regions

Electrophysiological Markers

Electroencephalography (EEG):

Progressive slowing of background activity
Epileptiform discharges
Myoclonic seizures

Visual Evoked Potentials (VEP):

Delayed or absent responses
Retinal degeneration indicators

Patient Management

Multidisciplinary Care

CLN7 disease requires comprehensive management:

Quality of Life Interventions

Environmental Modifications:

Safe home environment
Adaptive equipment
Visual aids

Educational Support:

Individualized education plans (IEPs)
Special education services
Communication devices

Family Support:

Genetic counseling
Support groups
Respite care coordination

Therapeutic Approaches

Gene Therapy

AAV-Mediated Gene Delivery: The most advanced therapeutic approach for CLN7 disease. Preclinical studies demonstrate:

AAV9-MFSD8 delivery rescues disease phenotype in mouse models[@chen2022]
Intravenous administration achieves widespread CNS delivery
Dose-dependent efficacy observed
Long-term expression achieved

Delivery strategies:

Intravenous AAV9 administration
Intrathecal AAV administration
Intracranial injection (direct CNS delivery)
Combination approaches

Current status: Clinical trials in planning/recruitment stages.

Small Molecule Therapies

Substrate reduction therapy: Develop compounds that reduce accumulation of toxic substrates:

Glycosphingolipid synthesis inhibitors
Autophagy enhancers
Lysosomal function modulators

Chaperone therapy: Small molecules that stabilize mutant MFSD8 protein:

Pharmacological chaperones under investigation
May restore partial function to missense variants

Anti-inflammatory therapies:

Microglial activation inhibitors
Anti-TNF approaches
Neuroprotective compounds

Supportive Care

Current management focuses on symptomatic treatment:

Seizure control:

Antiepileptic drugs (valproate, clonazepam, levetiracetam)
Ketogenic diet may reduce seizure frequency
Myoclonic seizure management

Visual impairment:

Low vision aids
Orientation and mobility training
Educational adaptations

Motor dysfunction:

Physical therapy
Occupational therapy
Assistive devices

Nutritional support:

Feeding assessment
Gastrostomy tube placement when needed

Behavioral management:

Structured environments
Communication aids
Behavioral interventions

Emerging Therapies

Enzyme Replacement Therapy

While challenging for membrane proteins, approaches under investigation include:

Recombinant MFSD8 delivery
Engineered enzyme variants
Brain-targeted delivery systems

Cell-Based Therapies

Hematopoietic Stem Cell Transplantation:

Potential source of lysosomal enzyme
May provide microglial replacement
Under investigation for other NCLs

Combination Approaches

Rational combinations being explored:

Gene therapy + substrate reduction
Gene therapy + anti-inflammatory
Multiple AAV serotypes for enhanced delivery

Prognosis and Outcomes

Disease Course

Typical Progression:

Progressive neurocognitive decline
Visual loss typically precedes severe motor impairment
Seizures worsen over time
Life expectancy: second to third decade typically

Factors Influencing Outcome:

Genotype (missense vs. null variants)
Age at symptom onset
Rate of disease progression
Quality of supportive care

End-of-Life Considerations

Focus on quality of life:

Comfort care
Pain management
Family support
Palliative care services

Current Research Directions

Biomarker Development

Research is focused on identifying:

Blood biomarkers: Lysosomal enzymes, inflammatory markers
Imaging biomarkers: MRI changes, PET tracers
Clinical biomarkers: Motor function scales, cognitive assessments

Clinical Trials

Several therapeutic approaches are advancing toward clinical translation:

AAV gene therapy trials (anticipated 2024-2025)
Small molecule clinical trials
Cell-based therapies under investigation

Gene Discovery and Diagnostics

Improved mutation screening methods
New variant classification approaches
Genotype-phenotype correlation studies
Population screening initiatives

Epidemiology

Prevalence

CLN7 disease is one of the rarer NCL subtypes:

Estimated prevalence: 1-2 per 1,000,000 births
Accounts for ~3-5% of all NCL cases
Higher incidence in certain populations (founder effects)

Geographic Distribution

Cases reported worldwide with higher frequency in:

Mediterranean populations
Middle Eastern populations
South Asian populations

Demographics

Equal male:female distribution
No ethnic predilection (except known founder mutations)
Typical onset: 2-7 years (variant late-infantile)

Differential Diagnosis

CLN7 disease should be differentiated from:

Other NCL subtypes:

[CLN1](/genes/cln1) (PPT1 infantile) - earlier onset
[CLN2](/genes/cln2) (TPP1 classic infantile) - classic infantile
[CLN3](/genes/cln3) (juvenile/Batten) - later onset, visual loss first
[CLN5](/genes/cln5) (Finnish variant) - different gene
[CLN6](/genes/cln6) (variant late-infantile) - different gene
[CLN8](/genes/cln8) (EPMR) - different phenotype

Other neurodegenerative disorders:

Rett syndrome (similar regression pattern)
Mitochondrial disorders
Leukodystrophies
Spinocerebellar ataxias

Key Publications

[Siintola E, et al. CLN7/MFSD8 mutations cause LINCL (2007)](https://pubmed.ncbi.nlm.nih.gov/17572665/)[@siintola2007]

[Mole SE, et al. NCL gene mutations and classifications (2019)](https://pubmed.ncbi.nlm.nih.gov/31085647/)[@mole2019]

[Kousi M, et al. CLN7/MFSD8 mutations cause variant LINCL (2009)](https://pubmed.ncbi.nlm.nih.gov/19201763/)[@kousi2009]

[Aiello C, et al. MFSD8/CLN7 frequent cause of variant LINCL (2009)](https://pubmed.ncbi.nlm.nih.gov/19177532/)[@aiello2009]

[Chen X, et al. AAV9/MFSD8 gene therapy effective (2022)](https://pubmed.ncbi.nlm.nih.gov/35025759/)[@chen2022]

[Lopez-Fabuel I, et al. PFKFB3 dysregulation in CLN7 (2022)](https://pubmed.ncbi.nlm.nih.gov/35087090/)[@lopez2022]

[Kousi M, et al. NCL mutation spectrum update (2012)](https://pubmed.ncbi.nlm.nih.gov/21990111/)[@kousi2012]

[Qiao Y, et al. Novel MFSD8 variants in Chinese family (2022)](https://pubmed.ncbi.nlm.nih.gov/35154277/)[@qiao2022]

[Kayani S, et al. CLN7 case series (2024)](https://pubmed.ncbi.nlm.nih.gov/39702211/)[@kayani2024]

[Mohammed A, et al. CLN3 and CLN7 localization (2017)](https://pubmed.ncbi.nlm.nih.gov/28365214/)[@mohammed2017]

[Ashwini A, et al. CLN7 in Chihuahuas (2016)](https://pubmed.ncbi.nlm.nih.gov/27211611/)[@ashwini2016]

[Craiu D, et al. Rett-like onset in CLN7 (2015)](https://pubmed.ncbi.nlm.nih.gov/25439737/)[@craiu2015]

[Leonard J, et al. Autophagy inhibition in CLN7 Drosophila (2016)](https://pubmed.ncbi.nlm.nih.gov/27878680/)[@leonard2016]

[Warrier V, et al. CLN7 clinical features and natural history (2013)](https://pubmed.ncbi.nlm.nih.gov/23294854/)[@warrier2013]

[Brand A, et al. Multi-omic approaches to NCL (2019)](https://pubmed.ncbi.nlm.nih.gov/31194117/)[@brand2019]

[Faller KM, et al. NCL: from childhood to therapy (2016)](https://pubmed.ncbi.nlm.nih.gov/27231251/)[@faller2016]

[Mole SE, et al. Molecular genetics of NCL (2005)](https://pubmed.ncbi.nlm.nih.gov/15645068/)[@mole2005]

[Williams RE, et al. Management of Batten disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27027527/)[@williams2016]

[Gera S, et al. AAV gene therapy for NCL (2018)](https://pubmed.ncbi.nlm.nih.gov/29344978/)[@gera2018]

External Links

[NCBI Gene: CLN7](https://www.ncbi.nlm.nih.gov/gene/256281)
[UniProt: MFSD8](https://www.uniprot.org/uniprot/Q8N5M4)
[GeneCards: CLN7](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLN7)
[OMIM: 614804](https://omim.org/entry/614804)
[Batten Disease Foundation](https://bdfa.org/)
[NCL Resource](https://www.ncl-resource.org/)

📖 View canonical wiki page →

Related Entities

CLN7

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-cln7
kg_node_id	CLN7
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0609681d04c4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-cln7'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

85%

Debates

0

Incoming

17

Outgoing

34

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CLN7 — Ceroid Lipofuscinosis, Neuronal 7 (MFSD8)

CLN7 — Ceroid Lipofuscinosis, Neuronal 7

CLN7 — Ceroid Lipofuscinosis, Neuronal 7

Overview

Gene Information

Protein Structure and Function

MFSD8 Structure

Lysosomal Transporter Function

Expression Pattern

Normal Biological Function

Lysosomal Transport

Autophagy and Lysosomal Function

Neuronal Homeostasis

Disease Mechanism

Pathogenesis Overview

Molecular Pathogenesis

Neuroinflammation

Clinical Presentation

Typical Disease Course

Core Clinical Features

Disease Subtypes

Diagnostic Findings

Genetics

Inheritance Pattern

Mutation Spectrum

Common Variants

Genotype-Phenotype Correlations

Expression Patterns

Tissue Distribution

Developmental Expression

Cell-Type Specificity

Signaling and Pathway

Animal Models

Canine Model

Drosophila Model

Mouse Models

Biomarkers and Diagnostic Markers

Fluid Biomarkers

Imaging Biomarkers

Electrophysiological Markers

Patient Management

Multidisciplinary Care

Quality of Life Interventions

Therapeutic Approaches

Gene Therapy

Small Molecule Therapies

Supportive Care

Emerging Therapies

Enzyme Replacement Therapy

Cell-Based Therapies

Combination Approaches

Prognosis and Outcomes

Disease Course

End-of-Life Considerations

Current Research Directions

Biomarker Development

Clinical Trials

Gene Discovery and Diagnostics

Epidemiology

Prevalence

Geographic Distribution

Demographics

Differential Diagnosis

Key Publications

See Also

External Links

💬 Discussion